object
sever
acut
respiratori
syndrom
sar
sever
pulmonari
infecti
diseas
caus
novel
coronaviru
develop
effect
specif
medicin
target
sarscoronaviru
cov
chimer
dnarna
hammerhead
ribozym
design
synthes
use
sequenc
homolog
mous
hepat
viru
mhv
method
chimer
dnarna
hammerhead
ribozym
target
mhv
sarscov
design
synthes
confirm
activ
vitro
cleavag
reaction
perform
synthes
ribozym
effect
chimer
ribozym
evalu
multipl
mhv
effect
chimer
ribozym
express
sarscov
evalu
cultur
cell
result
synthet
ribozym
cleav
synthet
target
mhv
sarscov
rna
fragment
predict
length
chimer
dnarna
hammerhead
ribozym
target
sarscov
significantli
inhibit
multipl
mhv
dbt
cell
chimer
dnarna
hammerhead
ribozym
target
sever
acut
respiratori
syndrom
sar
new
infecti
diseas
caus
novel
coronaviru
lead
deleteri
pulmonari
patholog
featur
peak
sar
outbreak
novemb
june
case
report
death
caus
organ
identifi
novel
coronaviru
sarscov
overal
mortal
outbreak
estim
overrid
clinic
featur
sar
rapid
mani
patient
develop
symptom
acut
respiratori
distress
syndrom
fulllength
genom
sequenc
sarscov
indic
envelop
positivestrand
rna
viru
famili
coronavirida
largest
known
nonseg
viral
rna
genom
kb
larg
corona
distinct
spike
envelop
coronavirus
make
identif
possibl
electron
microscopi
variou
drug
appli
treat
patient
contract
sar
specif
new
drug
vaccin
sarscov
wide
develop
howev
specif
cure
yet
produc
sar
thu
experiment
clinic
research
requir
produc
effect
therapeut
agent
nucleic
acid
medicin
show
promis
area
engin
inactiv
gene
function
import
elucid
function
particular
gene
may
also
use
gene
therapi
treatment
viral
infect
cancer
diseas
caus
aberr
gene
express
gene
function
inactiv
dna
level
nucleic
acid
medicin
antisens
oligodeoxynucleotid
rna
level
ribozym
sirna
develop
specif
molecular
antivir
therapi
would
landmark
advanc
medic
care
major
stumbl
block
achiev
specif
compound
toxic
viru
often
also
toxic
host
cell
oblig
intracellular
pathogen
resid
recent
antisens
technolog
specif
confer
level
nucleic
acid
sequenc
test
therapeut
potenti
one
approach
util
ribozym
ribozym
rna
molecul
hybrid
cleav
specif
target
rna
target
cleav
ribozym
dissoci
cleav
transcript
repeat
process
anoth
rna
molecul
major
advantag
ribozym
sequencespecif
cleav
multipl
target
mrna
molecul
wherea
antisens
molecul
cleav
target
molecul
reli
rnai
machineri
act
equimolar
ratio
last
year
ribozym
progress
subject
scientif
studi
potenti
therapeut
agent
treatment
acquir
inherit
diseas
develop
chimer
dnarna
hammerhead
ribozym
target
growth
factor
cardiovascular
renal
diseas
ribozym
shown
success
inhibit
gene
express
cancer
human
immunodefici
viru
demonstr
promis
technolog
ribozym
easili
degrad
rnase
vivo
henc
difficult
appli
chronic
diseas
howev
ribozym
could
still
use
success
acut
diseas
sar
studi
ribozym
specif
sar
develop
chimer
dnarna
hammerhead
ribozym
design
synthes
target
common
nucleotid
sequenc
sarscov
mous
hepat
viru
mhv
effect
suppress
mhv
sarscov
rna
express
evalu
vitro
avoid
doublestrand
structur
target
guc
cleavag
site
secondari
structur
sarscov
rna
nc
analyz
use
genetyxmac
second
structur
minimum
free
energi
softwar
packag
analysispredict
guc
sequenc
locat
nucleotid
loop
structur
sarscov
fig
target
homolog
rna
sequenc
around
cleavag
site
sarscov
rna
mhv
rna
shown
figur
chimer
dnarna
hammerhead
ribozym
design
ribonucleotid
noncatalyt
residu
replac
deoxyribonucleotid
two
phosphorothio
linkag
terminu
cleavag
guc
sequenc
mismatch
ribozym
threebas
chang
catalyt
core
design
control
fig
b
ribozym
target
rna
synthes
use
rna
polymeras
synthet
dna
templat
describ
previous
activ
templat
dna
strand
contain
region
class
iii
rna
polymeras
promot
follow
complement
rna
sequenc
desir
made
rna
synthesi
g
anneal
templat
mix
l
rna
polymeras
u
l
takara
biochem
osaka
japan
l
pctp
specif
activ
cim
new
england
nuclear
u
rnase
inhibitor
takara
biochem
l
transequencescript
reaction
buffer
trishcl
ph
rntp
mgcl
dtt
sperimidin
incub
h
phenol
chloroform
ad
mixtur
vortex
ribozym
centrifug
g
supernat
transfer
new
tube
mix
equal
amount
chloroform
isoamyl
alcohol
vortex
centrifug
g
supernat
mix
l
ethanol
centrifug
g
min
rna
pellet
wash
twice
ethanol
evapor
dissolv
l
diethyl
pyrocarbon
depc
treat
water
electrophoresi
l
rna
denatur
min
appli
polyacrylamid
sequenc
gel
h
electrophoresi
v
gel
expos
onto
film
min
rna
band
excis
gel
posit
indic
radioact
expos
film
recycl
rna
gel
contain
rna
band
cut
small
piec
l
depctreat
water
shaken
h
extract
rna
supernat
centrifug
rpm
min
mismatch
ribozym
fig
sequenc
target
rna
around
cleavag
site
common
sarscov
rna
mous
hepat
viru
rna
sequenc
ribozym
hybrid
includ
guc
underlin
b
sequenc
chimer
dnarna
hammerhead
ribozym
ribonucleotid
noncatalyt
residu
replac
deoxyribonucleotid
two
phosphorothio
linkag
ad
terminu
cleavag
guc
sequenc
sequenc
mismatch
ribozym
three
base
chang
catalyt
core
ribonucleotid
ribozym
underlin
phosphorothio
linkag
mark
asterisk
supernat
transfer
new
tube
mix
l
sodium
acet
ml
ethanol
incub
h
centrifug
rpm
min
rna
pellet
wash
twice
ethanol
evapor
rna
dissolv
l
depctreat
water
store
rna
concentr
determin
uv
spectrophotometri
use
spectrophotomet
shimadzu
co
tokyo
japan
vivo
experi
chimer
dnarna
hammerhead
ribozym
mismatch
ribozym
synthes
dnarna
synthes
appli
biosystem
foster
citi
calif
usa
purifi
highperform
liquid
chromatographi
vitro
cleavag
reaction
ribozym
perform
describ
previous
ribozym
anneal
target
rna
combin
n
ribozym
n
target
rna
l
trishcl
ph
heat
min
cool
min
cleavag
reaction
initi
ad
l
mgcl
anneal
ribozym
target
rna
cleavag
reaction
buffer
trishcl
ph
mgcl
incub
h
reaction
stop
addit
bromophenol
blue
solut
l
sampl
heat
min
cool
quickli
ice
l
sampl
load
onto
sequenc
gel
electrophoresi
gel
dri
expos
film
dbt
cell
seed
grown
dulbecco
modifi
eagl
medium
dmem
calf
serum
gibco
life
technolog
gaithersburg
md
usa
gml
amphotericin
b
mgml
kanamycin
serumfre
dbt
cell
transfect
ribozym
mismatch
ribozym
kda
polyethylenimin
reagent
incub
h
dbt
cell
infect
mhv
multipl
infect
min
cell
wash
twice
pb
incub
dmem
calf
serum
h
condit
medium
collect
mhv
titer
medium
determin
plaqu
assay
use
dbt
cell
viral
titer
express
plaqueform
unit
pfu
ml
revers
primer
total
volum
l
pcr
condit
consist
initi
denatur
min
follow
cycl
denatur
anneal
extens
min
final
extens
min
primer
rrna
includ
reaction
intern
control
pcr
product
separ
electrophoresi
agaros
gel
band
intens
measur
comput
analysi
use
nih
softwar
result
report
mean
sem
differ
mean
valu
evalu
student
test
p
valu
consid
signific
figur
show
vitro
cleavag
reaction
synthet
target
rna
chimer
dnarna
hammerhead
ribozym
target
sarscov
presenc
mgcl
synthet
ribozym
cleav
target
rna
encod
mhv
rna
sarscov
rna
respect
fragment
consist
predict
size
mismatch
ribozym
cleav
target
rna
indic
synthet
ribozym
specif
cleav
target
mhv
rna
sarscov
rna
figur
show
effect
chimer
dnarna
hammerhead
ribozym
target
sarscov
rna
multipl
mhv
dbt
cell
ribozym
transfect
dbt
cell
transfect
effici
fitclabel
ribozym
dbt
cell
kda
polyethylenimin
around
transfect
cell
infect
mhv
chimer
ribozym
target
sarscov
rna
significantli
reduc
viral
titer
medium
infect
cell
compar
cell
treat
mismatch
ribozym
figur
show
effect
chimer
ribozym
target
sarscov
rna
express
sarscov
rna
transcrib
recombin
plasmid
cell
concentr
n
chimer
ribozym
significantli
reduc
abund
sarscov
rna
dosedepend
manner
mismatch
ribozym
affect
express
sarscov
rna
date
sever
clinic
trial
ribozym
report
retrovir
express
ribozym
target
hiv
tat
current
phase
ii
test
patient
hivrel
lymphoma
antiangiogen
ribozym
target
current
phase
ii
trial
sever
tumor
type
ribozym
target
untransl
region
hepat
c
viru
rna
genom
recent
pass
phase
iii
clinic
trial
patient
chronic
hepat
c
hand
short
interf
rna
sirna
compos
doublestrand
rna
also
trigger
silenc
gene
express
sequencespecif
manner
shown
potenti
strong
nucleic
acid
medicin
sever
diseas
sirna
success
shown
inhibit
differ
stage
replic
howev
interferoninduc
effect
sirna
could
exert
nonspecif
inhibit
gene
express
remain
issu
develop
sirna
next
gener
gene
therapi
agent
virus
suscept
ribozym
may
aspect
viral
life
cycl
rna
depend
dna
intermedi
sever
class
ribozym
one
hammerhead
found
vivo
plant
viroid
virusoid
transcript
new
satellit
dna
natur
environ
enzym
cleav
intramolecularli
cut
requir
sequenc
usual
guc
hammerhead
ribozym
contain
two
function
modul
catalyt
core
cleav
target
rna
contain
sever
conserv
base
flank
region
nucleic
acid
complementar
direct
ribozym
core
specif
target
site
exploit
flexibl
two
modular
function
ribozym
could
potenti
design
specif
cleav
almost
target
rna
molecul
cleav
mrna
rapidli
degrad
allow
ribozym
dissoci
react
new
target
rna
cleavag
site
bind
arm
need
consid
ribozym
design
target
specif
rna
first
cleavag
site
locat
within
import
function
region
target
gene
ensur
correspond
protein
function
lost
cleavag
addit
flank
sequenc
around
cleavag
site
conserv
possibl
ribozym
cleavag
spectrum
remain
broad
sarscov
structur
compos
rna
encod
repricas
spike
envelop
membran
glycoprotein
nucleocapsid
protein
sinc
spike
structur
rna
sequenc
subject
rapid
mutagenesi
target
cleavag
site
ribozym
locat
viral
rna
sequenc
target
guc
cleavag
sequenc
ribozym
locat
within
stem
structur
target
mrna
mrna
function
suppress
secondari
structur
make
site
less
access
ensur
stem
structur
present
target
guc
cleavag
site
analyz
secondari
structur
sarscov
rna
select
optim
cleavag
site
bind
arm
target
loop
structur
expos
rna
sequenc
ribozym
cleavag
interact
experi
actual
sarscov
could
perform
present
studi
infect
risk
therefor
chimer
dnarna
hammerhead
ribozym
design
complementar
common
region
sarscov
mhv
includ
target
guc
sequenc
abil
ribozym
cleav
synthet
target
rna
encod
sarscov
rna
assess
vitro
effect
ribozym
inhibit
mvh
viru
multipl
evalu
dbt
cell
mhv
singlestrand
rna
viru
famili
coronavirida
belong
group
ii
coronavirus
clinic
infect
occur
viru
introduc
naiv
coloni
mice
coronavirus
typic
narrow
host
rang
fastidi
cell
cultur
mice
host
mhv
although
rodent
speci
may
carri
serum
antibodi
viru
cell
cultur
mhv
form
plaqu
upon
multipl
dbt
cell
present
studi
inhibit
multipl
mvh
approxim
transfect
effici
chimer
dnarna
ribozym
target
sarscov
dbt
cell
indic
ribozym
inhibit
viral
activ
addit
demonstr
chimer
ribozym
significantli
inhibit
express
synthet
sarscov
rna
transcrib
plasmid
cell
find
suggest
ribozym
could
use
treatment
sar
confirm
effect
ribozym
viral
multipl
vivo
experi
need
perform
mice
vivo
applic
chimer
ribozym
optim
method
deliveri
assess
advantag
applic
ribozym
target
sar
compar
vaccin
expect
rapid
applic
possibl
higher
effect
ribozym
treatment
howev
one
signific
problem
use
ribozym
gene
therapeut
degrad
ribozym
vivo
rna
ribozym
rapidli
degrad
cultur
medium
live
cell
rnase
diminish
copi
number
ribozym
thu
ribozym
therapi
suitabl
chronic
diseas
suitabl
acut
diseas
sar
ribozym
appli
tissu
high
catalyt
effici
stabil
adequ
level
ribozym
necessari
number
modif
improv
stabil
specif
efficaci
ribozym
ribozym
also
success
deliv
exogen
transfect
cell
cation
liposom
recent
studi
show
chimer
dnarna
hammerhead
ribozym
enhanc
catalyt
turnov
stabil
addit
chimer
ribozym
contain
phosphorothio
linkag
improv
resist
nucleas
present
studi
design
synthes
chimer
dnarna
hammerhead
ribozym
modifi
phosphorothio
linkag
terminu
deliveri
reagent
liposom
polyethylenimin
use
prevent
degrad
ribozym
sinc
polyethylenimin
report
protect
ribozym
degrad
nucleas
addit
assist
ribozym
deliveri
tissu
vivo
polyethylenimin
use
deliveri
reagent
ribozym
studi
sinc
sar
induc
pneumonia
deliveri
ribozym
intraven
air
way
would
benefici
studi
requir
determin
optim
method
therapeut
applic
ribozym
sarscov
studi
synthes
chimer
dnarna
ribozym
target
sarscov
significantli
inhibit
mhv
viral
activ
express
sarscov
rna
chimer
ribozym
feasibl
treatment
sar
